MultiSafepay Supporting 20,000 SMEs to Scale Through Payment Integration and Digitisation with Antom Technology Engine
MultiSafepay (MSP), an Amsterdam-based payment service provider, which became part of Ant International’s Antom, reported strong growth since its strategic integration with Antom, supporting thousands more SMEs in Europe to scale through innovative solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250417858076/en/
Ant International’s new office in Amsterdam City Centre will house MultiSafepay’s operations and enable further collaboration between its business pillars.
Since announcing its acquisition in July 2024, MSP has expanded its merchant base across Europe to 20,000+, an 11% increase. Transaction volumes surged by 44% year-on-year, reflecting customers' robust business growth as well as the addition of new top industry performers. Merchants are increasingly moving to unified payment services, in-person payments are now already at 8% of total volume processed across retail and food & beverage verticals - demonstrating the value of increased efficiency in operations and the benefits of enhancing customer touchpoints.
This acceleration displays the potential of Antom’s post-acquisition strategy to combine local expertise with a global technology suite, benefiting the merchants MSP serves with innovative digital technologies.
MSP provides merchants with unified payment capabilities, supporting more than 40 local and international payment methods, including cards, e-wallets, Buy Now Pay Later, internet banking, across in-person and online channels.
Since becoming wholly-owned subsidiary of Ant International, MSP has been integrating with Antom to help businesses improve operations, and scale with confidence, using the powerful solutions relied on by industry leaders globally. MSP will also look to work with other businesses of Ant International such as WorldFirst to offer inclusive financial services to its SME merchant base.
In under a year, the integration has propelled innovation for merchant expansion, improvements in payment success rates, and infrastructure upgrades, demonstrating the power of combining MSP’s 25-years of expertise with Antom’s global experience.
MSP’s total processed transaction volume is handled through in-person payments, using traditional payment terminal technology (such as C-TAP terminals) as well as Smart POS devices which offer merchants digital tools and do more than just accept payments. Supporting a range of technology gives merchants a flexible, cost-effective way to handle payments and demonstrates MSP’s dedication to helping small businesses thrive by offering a solution that fits their unique needs.
Olaf Geurs, CEO of MultiSafepay, commented: “We expect to exceed our 2025 growth projections given current strong numbers and deepened partnership with Ant International. The data shows how SME partners are embracing our joint innovative solutions with Antom to accelerate their digital operations. MultiSafepay's momentum underscores the value of our collaboration in empowering businesses to succeed in today's fast-evolving world.”
“Accelerating the adoption of new technologies like AI in merchant payment services enable us to raise efficiency while maximizing our expertise in the SME sector,” said Gary Liu, General Manager of Antom, Ant International. “By building on MultiSafepay’s platform and Antom’s global expertise, we’re making simple, flexible payments accessible to every business - no matter their size or ambition.”
The company has recently moved to Ant International’s new office in Amsterdam’s vibrant City Centre, enabling collaborations with other Ant International business pillars to directly benefit SMEs.
About Antom
Ant International's Antom is the leading payment and digitisation services provider for merchants around the world. It offers unified merchant payment solutions to serve businesses of all sizes. Antom supports merchants in over 50 countries and regions, enabling them to connect with consumers in more than 200 markets, with the flexibility to accept payments in more than 100 currencies. Beyond payments, it provides digital marketing solutions and merchant digitisation services to help merchant streamline operations and enhance customer engagement.
To learn more, please visit https://www.antom.com/.
About MultiSafepay
MultiSafepay is a leading Amsterdam-based payment service provider, combining decades of expertise with powerful in-house technology to help every business grow faster and compete with confidence, no matter their size or ambition.
By leveling the playing field in payments, we offer European businesses a simple, flexible solution for online, in-person, and unified payments, all through a single platform and integration. With a personal approach to payments, we optimize success rates, reduce complexity, and help your business do more, and earn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250417858076/en/
Contacts
Joshua Way, Ant International
Joshua.way@antgroup.com
Michiel van Werkhoven, MultiSafepay
michiel.vanwerkhoven@multisafepay.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press Release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press Release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press Release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press Release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom